Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders (2011 - 2026)

Ani Pharmaceuticals has reported Net Income towards Common Stockholders for 16 years, with the latest figure at $29.5 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 93.07% year-over-year to $29.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $91.4 million (up 503.11% YoY) and the FY2025 annual result came in at $77.2 million, up 483.08% from the prior year.
• Net Income towards Common Stockholders climbed to $29.5 million in Q1 2026 per ANIP's latest filing, from $27.5 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $29.5 million in Q1 2026 and troughed at -$24.6 million in Q3 2024.
• A 5-year average of $3.2 million and a median of $1.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders tumbled 25451.85% in 2022, then jumped 1623.23% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$4.6 million in 2022, then surged by 116.11% to $749000.0 in 2023, then tumbled by 1526.17% to -$10.7 million in 2024, then jumped by 357.35% to $27.5 million in 2025, then rose by 7.28% to $29.5 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $29.5 million, $27.5 million, and $26.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.